智通财经APP讯，荃信生物-B(02509)发布截至2025年6月30日止6个月业绩，该集团取得收入人民币2.06亿元(单位下同)，同比增加359.69%;研发开支1.51亿元，同比增加4.25%;期内亏损3093.3万元，同比减少83.11%;每股亏损0.13元。
截至2025年6月30日止6个月，本集团收入为2.06亿元，主要包括来自授权协议的收入，包括与QX030N海外授权有关的首付款及Caldera Therapeutics,Inc.约24.88%股权的非现金代价，以及QX004N III期首例入组的里程碑费用，合计1.81亿元;及CDMO服务产生的收入及QX004N和QX008N项目提供研发服务约2200万元。
我们的研发开支由截至2024年6月30日止6个月的1.45亿元增加4.25%至截至2025年6月30日止6个月的1.51亿元，其中以权益结算股份支付摊销减少587万元，研发支出增加1204万元，主要为公司临床试验推进导致的临床试验费用增加。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.